803 related articles for article (PubMed ID: 26928463)
1. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.
Kumar A; Coleman I; Morrissey C; Zhang X; True LD; Gulati R; Etzioni R; Bolouri H; Montgomery B; White T; Lucas JM; Brown LG; Dumpit RF; DeSarkar N; Higano C; Yu EY; Coleman R; Schultz N; Fang M; Lange PH; Shendure J; Vessella RL; Nelson PS
Nat Med; 2016 Apr; 22(4):369-78. PubMed ID: 26928463
[TBL] [Abstract][Full Text] [Related]
2. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
Davis JN; Wojno KJ; Daignault S; Hofer MD; Kuefer R; Rubin MA; Day ML
Cancer Res; 2006 Dec; 66(24):11897-906. PubMed ID: 17178887
[TBL] [Abstract][Full Text] [Related]
3. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.
Friedlander TW; Roy R; Tomlins SA; Ngo VT; Kobayashi Y; Azameera A; Rubin MA; Pienta KJ; Chinnaiyan A; Ittmann MM; Ryan CJ; Paris PL
Cancer Res; 2012 Feb; 72(3):616-25. PubMed ID: 22158653
[TBL] [Abstract][Full Text] [Related]
4. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
5. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
6. Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins.
Su S; Minges JT; Grossman G; Blackwelder AJ; Mohler JL; Wilson EM
J Biol Chem; 2013 Aug; 288(34):24809-24. PubMed ID: 23853093
[TBL] [Abstract][Full Text] [Related]
7. Loss of photoreceptorness and gain of genomic alterations in retinoblastoma reveal tumor progression.
Kooi IE; Mol BM; Moll AC; van der Valk P; de Jong MC; de Graaf P; van Mil SE; Schouten-van Meeteren AY; Meijers-Heijboer H; Kaspers GL; Te Riele H; Cloos J; Dorsman JC
EBioMedicine; 2015 Jul; 2(7):660-70. PubMed ID: 26288838
[TBL] [Abstract][Full Text] [Related]
8. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M
Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065
[TBL] [Abstract][Full Text] [Related]
9. The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma.
Bianchi-Frias D; Hernandez SA; Coleman R; Wu H; Nelson PS
Mol Cancer Res; 2015 Feb; 13(2):339-47. PubMed ID: 25298407
[TBL] [Abstract][Full Text] [Related]
10. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract][Full Text] [Related]
11. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
12. Genomic instability and proliferation/survival pathways in RB1-deficient malignancies.
Pappas L; Xu XL; Abramson DH; Jhanwar SC
Adv Biol Regul; 2017 May; 64():20-32. PubMed ID: 28242412
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ
Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885
[TBL] [Abstract][Full Text] [Related]
14. Genomic and Clinicopathologic Characterization of
Kaur H; Salles DC; Murali S; Hicks JL; Nguyen M; Pritchard CC; De Marzo AM; Lanchbury JS; Trock BJ; Isaacs WB; Timms KM; Antonarakis ES; Lotan TL
Clin Cancer Res; 2020 Sep; 26(18):4869-4881. PubMed ID: 32694154
[TBL] [Abstract][Full Text] [Related]
15. High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer.
Wu Y; Schoenborn JR; Morrissey C; Xia J; Larson S; Brown LG; Qu X; Lange PH; Nelson PS; Vessella RL; Fang M
J Mol Diagn; 2016 Jan; 18(1):131-43. PubMed ID: 26607774
[TBL] [Abstract][Full Text] [Related]
16. Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.
Folk WP; Kumari A; Iwasaki T; Pyndiah S; Johnson JC; Cassimere EK; Abdulovic-Cui AL; Sakamuro D
J Biol Chem; 2019 Apr; 294(14):5700-5719. PubMed ID: 30733337
[TBL] [Abstract][Full Text] [Related]
17. AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy.
Zekri A; Ghaffari SH; Ghanizadeh-Vesali S; Yaghmaie M; Salmaninejad A; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
Tumour Biol; 2015 Feb; 36(2):623-32. PubMed ID: 25277659
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Genomic Profiling of Androgen-Receptor-Negative Canine Prostate Cancer.
Laufer-Amorim R; Fonseca-Alves CE; Villacis RAR; Linde SAD; Carvalho M; Larsen SJ; Marchi FA; Rogatto SR
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925701
[TBL] [Abstract][Full Text] [Related]
19. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.
Choucair K; Ejdelman J; Brimo F; Aprikian A; Chevalier S; Lapointe J
BMC Cancer; 2012 Nov; 12():543. PubMed ID: 23171135
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases.
Aryee MJ; Liu W; Engelmann JC; Nuhn P; Gurel M; Haffner MC; Esopi D; Irizarry RA; Getzenberg RH; Nelson WG; Luo J; Xu J; Isaacs WB; Bova GS; Yegnasubramanian S
Sci Transl Med; 2013 Jan; 5(169):169ra10. PubMed ID: 23345608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
